UNSPSC 51433503: Mibefradil

This classification denotes a calcium channel blocker with the molecular formula C29H38FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27B90X776A, chemically known as acetic acid, methoxy-, 2-(2-((3-(1h-benzimidazol-2-yl)propyl)methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester, dihydrochloride, (1s-cis)- but generally known as mibefradil, which bears US NIH Compound Identifier 60662.

UNSPSC 51433503 Mibefradil, a Commodity code, encompasses pharmaceutical products supplied to state and local health and human services agencies, emergency medical services, and cooperative purchasing alliances for use in emergency care, pharmacy benefit programs, and institutional healthcare delivery. State and local governments buy individual medications and multi-source generic pharmaceuticals under this code to stock emergency response vehicles, hospital formularies, and centralized pharmacy distribution networks. The issuing bodies include municipal fire and rescue departments (Tampa Fire Rescue via the City of Tampa), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which serves state and local government facilities across participating jurisdictions including Minnesota and Oregon). Recent solicitations show a mix of small emergency-supply procurements and large multi-year framework agreements serving regional and multi-state distribution channels.

Recent activity is concentrated in Florida and the Upper Midwest, with exploratory procurement also underway in Texas. The City of Tampa's Purchasing Department issued IFB 26-P-00188 on April 24, 2026, for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) with a due date of April 8, 2026, and an estimated contract value of $40,000, sheltered with a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, though as a Request for Information rather than a formal solicitation, it indicates early-stage procurement planning without committed budget or timeline. The Minnesota Department of Administration, on behalf of MMCAP, issued RFP S1070000015802 on January 20, 2026, for Generic Multi Source Pharmaceuticals and OTC Products, with responses due March 26, 2026, requiring vendor certification of cGMP and Drug Supply Chain Security Act compliance, relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), and competitive pricing weighted 75 percent in evaluation; the contract term is two years from a July 1, 2026, effective date.